Children who passed this challenge at 24 months were placed on a diet
with ad libitum egg consumption and were evaluated for continuation of sustained unresponsiveness at 30 months and 36 months.
RESULTS
After 10 months of therapy, none of the children who received placebo and 55% of those who received oral immunotherapy passed the oral food challenge and were considered to be desensitized; after 22 months, 75% of children in the oral-immunotherapy group were desensitized. In the oral-immunotherapy group, 28% (11 of 40 children) passed the oral food challenge at 24 months and were considered to have sustained unresponsiveness. At 30 months and 36 months, all children who had passed the oral food challenge at 24 months were consuming egg. Of the immune markers measured, small wheal diameters on skin-prick testing and increases in egg-specific selleck compound IgG4 antibody levels selleck kinase inhibitor were associated with passing the oral food challenge at 24 months.
CONCLUSIONS
These results show that oral immunotherapy can desensitize a high proportion of children with egg allergy and induce sustained unresponsiveness in a clinically
significant subset. (Funded by the National Institutes of Health; ClinicalTrials.gov number, NCT00461097.)”
“Background: Postthrombotic syndrome (PTS) is a common complication after iliofemoral venous thrombosis, often resulting in poor quality of life (QOL) among the affected patients. This study assessed development of PTS and its effect on QOL among patients treated for iliofemoral venous thrombosis by catheter-directed thrombolysis.
Methods: Patients admitted with an iliofemoral venous thrombosis and treated with catheter-directed thrombolysis at Gentofte University Hospital from 1999 to 2008 were invited to participate. Duplex ultrasound imaging was used
to assess venous patency and valve function. Each patient completed the generic Short-Form 36-item (SF-36) health survey assessment, producing physical component (PCS) and mental component summary (MCS) scores, and the disease-specific Venous Insufficiency Epidemiological and Economic Study (VEINES)-Quality of Life (QOL)/Symptoms (Sym), questionnaires to assess QOL. PTS was assessed cAMP using the Villalta scale.
Results: The study included 109 patients. Median follow-up was 71 months. PTS developed in 18 patients (16.5%) and of those, initial thrombolysis was successful in 13. Patients with PTS had significantly worse mean +/- standard deviation scores than patients without PTS on VEINES-QOL (34.2 +/- 9.6 vs 53.1 +/- 6.6; P < .0001), VEINES-Sym (34.0 +/- 8.8 vs 53.2 +/- 6.6; P < .0001), SF-36 MCS (44.2 +/- 15.5 vs 52.3 +/- 11.0; P = .005), and SF-36 PCS (42.3 +/- 9.1 vs 53.5 +/- 7.8; P < .0001) subscales. Patients with reflux or chronic occlusions, or both, had significantly lower mean +/- SD scores than patients with patent veins without reflux on VEINES-QOL (43.5 +/- 14.3 vs 51.0 +/- 8.8; P = .044) and SF-36 PCS (47.2 +/- 10.9 vs 52.4 +/- 8.